Dyadic says its chief scientific officer to make presentation during EU Innovative Medicines Initiative ZAPI Stakeholders virtual meeting

Dyadic International, Inc. (NASDAQ:DYAI) has announced that Ronen Tchelet, the company’s chief scientific officer, will make a presentation during the European Union Innovative Medicines Initiative (IMI) Zoonotic Anticipation Preparedness Initiative (ZAPI) Stakeholders Virtual Web Meeting to be held on February 4 and 5, 2020.

“Dyadic’s C1 gene expression platform has played an important role in the success of the ZAPI project,” said Mark Emalfarb, Dyadic’s CEO in a statement.

“Our participation in the ZAPI project has led to several fully funded animal health collaborations outside of ZAPI as well as helping accelerate the development of our C1 technology which is being used to facilitate a fast, coordinated, and practical response to the current COVID-19 pandemic and help to better prepare industry and governments to combat new infectious diseases as soon as they emerge,” Emalfarb added.

READ: Dyadic unveils fully-funded collaboration with TurtleTree Scientific to develop a number of recombinant protein growth factors

Dr Tchelet commented: ”In the ZAPI project, and subsequently in our SARS-CoV-2 antigen programs, we have demonstrated that C1 is a robust and highly productive cell line for a number of gene expression challenges related to the production of antigens for the Schmallenberg virus (SBV) and Rift Valley Fever (RVFV). One of our key accomplishments in the ZAPI program, was that the C1 gene expression platform had far better results as compared to the baculovirus cells for both the SBV and RVFV antigens, enabling the ZAPI project to meet its objectives of producing a sufficient amount of low-cost doses with reduced fermentation volume capacity.”

Dr Tchelet will present Dyadic slides in sessions 2b and 2c on Thursday, February 4.

The IMI launched ZAPI in March 2015 to set up methodologies and platform technologies that would be ready to put into production for vaccines and neutralizing monoclonal antibodies to efficiently counter emerging or remerging zoonotic viruses.

​​​​​​Six years later, the ZAPI project has made great strides in vaccine and antibody design, and new approaches for achieving the “surge manufacturing capacity” objective. The Final Stakeholders Global Meeting will present an overview of the main findings and key learnings from the ZAPI project partnership’s experience for improving our One Health preparedness status for facing effectively future pandemics.

“Within the collaboration, we helped to validate a prolific fungus, developed by one of our project partners, Dyadic, who demonstrated that their C1 technology can be used to churn out vaccines and antibodies in unprecedented amounts which has the potential to further accelerate biologic manufacturing processes,” said project coordinator Dr Jean-Christophe Audonnet.

“Dyadic and its C1 cell line far exceeded our initial expectations at the start of the program, turning in record antigen productivity for both the SBV and RVFV antigens,” he added.

The ZAPI Stakeholders Final Conference Virtual Meeting is an open conference, and all details are available at https://zapi-stakeholders-final-conference.iabs.org/. Investors who would like to listen in need to register in advance at https://www.iabs.org/zapi-stakeholders-final-conference. The times posted on the website link above are CET time, six hours ahead of EST time.

Contact the author at [email protected]

Story by ProactiveInvestors